Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sana Biotechnology, Inc. (SANA)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/10/2023
8-K
Quarterly results
08/21/2023
8-K
Termination of a Material Definitive Agreement Interactive Data
08/03/2023
10-Q
Quarterly Report for the period ended June 30, 2023
08/03/2023
8-K
Quarterly results
Docs:
"
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted allogeneic hypoimmune-modified islet cells evade rejection and control glucose without immunosuppression or insulin treatment in non-human primate diabetes study Data published in Science Translational Medicine, Natur...
"
06/09/2023
8-K
Submission of Matters to a Vote of Security Holders Interactive Data
06/07/2023
144
Form 144 - Report of proposed sale of securities:
06/07/2023
144
Form 144 - Report of proposed sale of securities:
06/07/2023
8-K
Investor presentation
Docs:
"
CAR 4 CD22 CD19 BCMA GPRC5D
"
05/24/2023
144
Form 144 - Report of proposed sale of securities:
05/24/2023
144/A
Form 144/A - Report of proposed sale of securities: [Amend]
05/24/2023
144
Form 144 - Report of proposed sale of securities:
05/08/2023
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023
10-Q
Quarterly Report for the period ended March 31, 2023
05/08/2023
8-K
Quarterly results
Docs:
"
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year
"
05/02/2023
EFFECT
Form EFFECT - Notice of Effectiveness:
05/01/2023
POS EX
Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
04/28/2023
ARS
Form ARS - Annual Report to Security Holders:
04/28/2023
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023
DEF 14A
Form DEF 14A - Other definitive proxy statements:
04/26/2023
SC 13G
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/16/2023
POS AM
Form POS AM - Post-Effective amendments for registration statement:
03/16/2023
10-K
Annual Report for the period ended December 31, 2022
03/16/2023
8-K
Quarterly results
Docs:
"
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Announced SC291 IND clearance with goal to report initial clinical data this year
"
03/15/2023
POSASR
Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/13/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023
SC 13G/A
FMR LLC reports a 4.8% stake in SANA BIOTECHNOLOGY INC
01/26/2023
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies Goal is to report initial SC291 clinical data this year
"
01/26/2023
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
"
01/20/2023
SC 13G/A
BAILLIE GIFFORD & CO reports a 5.6% stake in Sana Biotechnology, Inc.
01/10/2023
8-K
Investor presentation
Docs:
"
Corporate Presentation
"
11/29/2022
8-K
Quarterly results
11/02/2022
10-Q
Quarterly Report for the period ended September 30, 2022
11/02/2022
8-K
Quarterly results
11/01/2022
8-K
Quarterly results
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy